

Bernard Laurent Schneider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/232246/publications.pdf>

Version: 2024-02-01

118
papers

9,220
citations

41323

49
h-index

43868

91
g-index

123
all docs

123
docs citations

123
times ranked

14727
citing authors

#	ARTICLE	IF	CITATIONS
1	Â-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10813-10818.	3.3	488
2	Î±-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer. <i>Journal of Biological Chemistry</i> , 2012, 287, 15345-15364.	1.6	466
3	In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons. <i>Cell Metabolism</i> , 2016, 23, 94-102.	7.2	437
4	Endoplasmic Reticulum Stress Is Important for the Manifestations of Î±-Synucleinopathy In Vivo. <i>Journal of Neuroscience</i> , 2012, 32, 3306-3320.	1.7	319
5	Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an Â-synuclein rat model of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17510-17515.	3.3	310
6	Behaviour-dependent recruitment of long-range projection neurons in somatosensory cortex. <i>Nature</i> , 2013, 499, 336-340.	13.7	301
7	Long-range connectivity of mouse primary somatosensory barrel cortex. <i>European Journal of Neuroscience</i> , 2010, 31, 2221-2233.	1.2	285
8	Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits Î±-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. <i>Journal of Neuroscience</i> , 2010, 30, 3184-3198.	1.7	271
9	Insulin-Like Growth Factor-I Is Necessary for Neural Stem Cell Proliferation and Demonstrates Distinct Actions of Epidermal Growth Factor and Fibroblast Growth Factor-2. <i>Journal of Neuroscience</i> , 2001, 21, 7194-7202.	1.7	239
10	Cortico-reticulo-spinal circuit reorganization enables functional recovery after severe spinal cord contusion. <i>Nature Neuroscience</i> , 2018, 21, 576-588.	7.1	228
11	Tmc gene therapy restores auditory function in deaf mice. <i>Science Translational Medicine</i> , 2015, 7, 295ra108.	5.8	222
12	Large-Scale Chondroitin Sulfate Proteoglycan Digestion with Chondroitinase Gene Therapy Leads to Reduced Pathology and Modulates Macrophage Phenotype following Spinal Cord Contusion Injury. <i>Journal of Neuroscience</i> , 2014, 34, 4822-4836.	1.7	200
13	Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6804-6809.	3.3	183
14	Phosphorylation Does Not Prompt, Nor Prevent, the Formation of Â-synuclein Toxic Species in a Rat Model of Parkinson's Disease. <i>Human Molecular Genetics</i> , 2009, 18, 872-87.	1.4	172
15	Channel-Mediated Lactate Release by K ⁺ -Stimulated Astrocytes. <i>Journal of Neuroscience</i> , 2015, 35, 4168-4178.	1.7	163
16	Polo-like kinase 2 regulates selective autophagic Î±-synuclein clearance and suppresses its toxicity in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E3945-54.	3.3	160
17	Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. <i>Gene Therapy</i> , 2006, 13, 379-388.	2.3	159
18	Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. <i>Nature Medicine</i> , 2019, 25, 1123-1130.	15.2	149

#	ARTICLE	IF	CITATIONS
19	Pathway-specific reorganization of projection neurons in somatosensory cortex during learning. <i>Nature Neuroscience</i> , 2015, 18, 1101-1108.	7.1	146
20	Regulation of Memory Formation by the Transcription Factor XBP1. <i>Cell Reports</i> , 2016, 14, 1382-1394.	2.9	142
21	A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2. <i>Journal of Neuroscience</i> , 2011, 31, 907-912.	1.7	135
22	Nigrostriatal overabundance of α -synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. <i>Acta Neuropathologica</i> , 2012, 123, 653-669.	3.9	132
23	Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. <i>Human Molecular Genetics</i> , 2014, 23, 4621-4638.	1.4	126
24	Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain. <i>Journal of Clinical Investigation</i> , 2013, 123, 3002-3013.	3.9	113
25	Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. <i>Gene Therapy</i> , 2010, 17, 141-146.	2.3	112
26	Systemic AAV6 Delivery Mediating RNA Interference Against SOD1: Neuromuscular Transduction Does Not Alter Disease Progression in fALS Mice. <i>Molecular Therapy</i> , 2008, 16, 1018-1025.	3.7	105
27	Sustained expression of PGC-1 α in the rat nigrostriatal system selectively impairs dopaminergic function. <i>Human Molecular Genetics</i> , 2012, 21, 1861-1876.	1.4	105
28	Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. <i>Experimental Neurology</i> , 2015, 265, 48-58.	2.0	104
29	The RNA-Binding Protein PUM2 Impairs Mitochondrial Dynamics and Mitophagy During Aging. <i>Molecular Cell</i> , 2019, 73, 775-787.e10.	4.5	100
30	Measurement of autophagy flux in the nervous system in vivo. <i>Cell Death and Disease</i> , 2013, 4, e917-e917.	2.7	97
31	Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS. <i>Nature Neuroscience</i> , 2015, 18, 227-238.	7.1	85
32	Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α -Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 1536-1544.	1.7	84
33	FOXO3 determines the accumulation of α -synuclein and controls the fate of dopaminergic neurons in the substantia nigra. <i>Human Molecular Genetics</i> , 2014, 23, 1435-1452.	1.4	84
34	Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons. <i>Journal of Neuroscience Methods</i> , 2011, 201, 228-238.	1.3	80
35	Parkinson's Disease: Gene Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009431-a009431.	2.9	80
36	Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. <i>Neurobiology of Disease</i> , 2006, 22, 119-129.	2.1	79

#	ARTICLE	IF	CITATIONS
37	Using human neural stem cells to model neurological disease. <i>Nature Reviews Genetics</i> , 2004, 5, 136-144.	7.7	75
38	Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. <i>Journal of Neuroscience Methods</i> , 2007, 163, 338-349.	1.3	75
39	PGC-1 β activity in nigral dopamine neurons determines vulnerability to α -synuclein. <i>Acta Neuropathologica Communications</i> , 2015, 3, 16.	2.4	74
40	PM20D1 is a quantitative trait locus associated with Alzheimer's disease. <i>Nature Medicine</i> , 2018, 24, 598-603.	15.2	73
41	Altered interplay between endoplasmic reticulum and mitochondria in Charcot-Marie-Tooth type 2A neuropathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2328-2337.	3.3	73
42	Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship?. <i>Cell Death and Disease</i> , 2018, 9, 333.	2.7	69
43	Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. <i>Human Molecular Genetics</i> , 2007, 16, 651-666.	1.4	68
44	Central anorexigenic actions of bile acids are mediated by TGR5. <i>Nature Metabolism</i> , 2021, 3, 595-603.	5.1	64
45	Rab1A Over-Expression Prevents Golgi Apparatus Fragmentation and Partially Corrects Motor Deficits in an Alpha-Synuclein Based Rat Model of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 373-387.	1.5	61
46	Chondroitinase gene therapy improves upper limb function following cervical contusion injury. <i>Experimental Neurology</i> , 2015, 271, 131-135.	2.0	58
47	Loss of MITF expression during human embryonic stem cell differentiation disrupts retinal pigment epithelium development and optic vesicle cell proliferation. <i>Human Molecular Genetics</i> , 2014, 23, 6332-6344.	1.4	55
48	Efficient viral transduction in mouse inner ear hair cells with utricle injection and AAV9-PHP.B. <i>Hearing Research</i> , 2020, 394, 107882.	0.9	55
49	Mitofusin-2 in the Nucleus Accumbens Regulates Anxiety and Depression-like Behaviors Through Mitochondrial and Neuronal Actions. <i>Biological Psychiatry</i> , 2021, 89, 1033-1044.	0.7	55
50	Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. <i>Neurobiology of Disease</i> , 2009, 35, 32-41.	2.1	54
51	A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells. <i>Biomaterials</i> , 2014, 35, 779-791.	5.7	54
52	Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord. <i>Human Gene Therapy</i> , 2014, 25, 109-120.	1.4	54
53	SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 167-184.	1.7	54
54	Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice. <i>Molecular Therapy</i> , 2011, 19, 274-283.	3.7	53

#	ARTICLE	IF	CITATIONS
55	Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles. <i>Human Gene Therapy</i> , 2013, 24, 613-629.	1.4	51
56	Parkin functionally interacts with PGC-1 β to preserve mitochondria and protect dopaminergic neurons. <i>Human Molecular Genetics</i> , 2017, 26, ddw418.	1.4	50
57	α -Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. <i>Biomolecules</i> , 2015, 5, 2675-2700.	1.8	49
58	An R-CaMP1.07 reporter mouse for cell-type-specific expression of a sensitive red fluorescent calcium indicator. <i>PLoS ONE</i> , 2017, 12, e0179460.	1.1	47
59	A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. <i>Human Molecular Genetics</i> , 2014, 23, 4887-4905.	1.4	45
60	Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 14-26.	1.8	45
61	α -Synuclein increases β -amyloid secretion by promoting β -secretase processing of APP. <i>PLoS ONE</i> , 2017, 12, e0171925.	1.1	45
62	Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2015, 77, 49-61.	2.1	44
63	Proton and Phosphorus Magnetic Resonance Spectroscopy of a Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, S87-S99.	1.2	40
64	Axonal Localization of Integrins in the CNS Is Neuronal Type and Age Dependent. <i>ENeuro</i> , 2016, 3, ENEURO.0029-16.2016.	0.9	40
65	Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System. <i>International Journal of Molecular Sciences</i> , 2015, 16, 10578-10600.	1.8	39
66	An <i>in vivo</i> ultrahigh field 14.1T ¹ H-MRS study on 6-OHDA and α -synuclein-based rat models of Parkinson's disease: GABA as an early disease marker. <i>NMR in Biomedicine</i> , 2013, 26, 43-50.	1.6	37
67	G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. <i>Human Molecular Genetics</i> , 2018, 27, 120-134.	1.4	37
68	Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. <i>Molecular Therapy</i> , 2003, 7, 506-514.	3.7	36
69	Single and Dual Vector Gene Therapy with AAV9-PHP.B Rescues Hearing in Tmc1 Mutant Mice. <i>Molecular Therapy</i> , 2021, 29, 973-988.	3.7	36
70	Long-Term Doxycycline-Regulated Secretion of Erythropoietin by Encapsulated Myoblasts. <i>Molecular Therapy</i> , 2002, 6, 155-161.	3.7	35
71	Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects. <i>Scientific Reports</i> , 2017, 7, 13556.	1.6	35
72	Survival of Encapsulated Human Primary Fibroblasts and Erythropoietin Expression Under Xenogeneic Conditions. <i>Human Gene Therapy</i> , 2004, 15, 669-680.	1.4	34

#	ARTICLE	IF	CITATIONS
73	Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. <i>Experimental Neurology</i> , 2013, 247, 359-372.	2.0	34
74	A subcutaneous cellular implant for passive immunization against amyloid- β^2 reduces brain amyloid and tau pathologies. <i>Brain</i> , 2016, 139, 1587-1604.	3.7	33
75	Modulating the catalytic activity of AMPK has neuroprotective effects against α -synuclein toxicity. <i>Molecular Neurodegeneration</i> , 2017, 12, 80.	4.4	33
76	Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. <i>Kidney International</i> , 2002, 62, 1395-1401.	2.6	32
77	α -Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9). <i>Neurobiology of Disease</i> , 2015, 73, 229-243.	2.1	32
78	Regulation of Prenatal Human Retinal Neurosphere Growth and Cell Fate Potential by Retinal Pigment Epithelium and Mash1. <i>Stem Cells</i> , 2008, 26, 3182-3193.	1.4	29
79	The adipocyte differentiation protein APMAP is an endogenous suppressor of $A\beta^2$ production in the brain. <i>Human Molecular Genetics</i> , 2015, 24, 371-382.	1.4	28
80	Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development. <i>European Journal of Medical Genetics</i> , 2018, 61, 685-698.	0.7	28
81	The Links between ALS and NF- κ B. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3875.	1.8	28
82	Amyloid- β^2 plaque deposition measured using propagation-based X-ray phase contrast CT imaging. <i>Journal of Synchrotron Radiation</i> , 2016, 23, 813-819.	1.0	27
83	In vivo neurochemical measurements in cerebral tissues using a droplet-based monitoring system. <i>Nature Communications</i> , 2017, 8, 1239.	5.8	26
84	Glutaredoxin1 Diminishes Amyloid Beta-Mediated Oxidation of F-Actin and Reverses Cognitive Deficits in an Alzheimer's Disease Mouse Model. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 1321-1338.	2.5	25
85	Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate. <i>JCI Insight</i> , 2018, 3, .	2.3	24
86	Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?. <i>Frontiers in Neuroanatomy</i> , 2016, 10, 123.	0.9	23
87	Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1283-1298.	2.4	22
88	The exercise-induced long noncoding RNA <i>CYTOR</i> promotes fast-twitch myogenesis in aging. <i>Science Translational Medicine</i> , 2021, 13, eabc7367.	5.8	19
89	Alpha-synuclein ferrireductase activity is detectible in vivo, is altered in Parkinson's disease and increases the neurotoxicity of DOPAL. <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 1-11.	1.0	18
90	PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 870-878.	0.9	16

#	ARTICLE	IF	CITATIONS
91	SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 354-377.e3.	2.3	16
92	Viral vectors, animal models and new therapies for Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, S169-S171.	1.1	15
93	Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease. International Journal of Neuroscience, 2017, 127, 28-36.	0.8	15
94	Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation. Biomaterials, 2014, 35, 792-802.	5.7	14
95	CSP β reduces aggregates and rescues striatal dopamine release in α -synuclein transgenic mice. Brain, 2021, 144, 1661-1669.	3.7	14
96	A self-immunomodulating myoblast cell line for erythropoietin delivery. Gene Therapy, 2001, 8, 58-66.	2.3	13
97	Overview of Mouse Models of Parkinson's Disease. Current Protocols in Mouse Biology, 2014, 4, 121-139.	1.2	13
98	Dopamine and Methamphetamine Differentially Affect Electron Transport Chain Complexes and Parkin in Rat Striatum: New Insight into Methamphetamine Neurotoxicity. International Journal of Molecular Sciences, 2022, 23, 363.	1.8	13
99	IL10- and IL35-Secreting MutuDC Lines Act in Cooperation to Inhibit Memory T Cell Activation Through LAG-3 Expression. Frontiers in Immunology, 2021, 12, 607315.	2.2	11
100	Astrocyte-targeting scRNA interference against mutated superoxide dismutase 1 induces motoneuron plasticity and protects fast-fatigable motor units in a mouse model of amyotrophic lateral sclerosis. Glia, 2022, 70, 842-857.	2.5	10
101	INDUCING HOST ACCEPTANCE TO ENCAPSULATED XENOGENEIC MYOBLASTS. Transplantation, 2001, 71, 345-351.	0.5	9
102	Nano-imaging trace elements at organelle levels in substantia nigra overexpressing α -synuclein to model Parkinson's disease. Communications Biology, 2020, 3, 364.	2.0	9
103	Inducing Tolerance to a Soluble Foreign Antigen by Encapsulated Cell Transplants. Molecular Therapy, 2006, 13, 447-456.	3.7	8
104	Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model. Neurobiology of Aging, 2013, 34, 1355-1368.	1.5	8
105	Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice. Movement Disorders, 2020, 35, 1843-1853.	2.2	8
106	Blood Flow to the Spleen is Altered in a Mouse Model of Spinal Muscular Atrophy. Journal of Neuromuscular Diseases, 2020, 7, 315-322.	1.1	8
107	Anti-A β antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology. Acta Neuropathologica Communications, 2020, 8, 198.	2.4	7
108	Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy. Gene Therapy, 2022, 29, 544-554.	2.3	6

#	ARTICLE	IF	CITATIONS
109	Scalable Production and Purification of Adeno-Associated Viral Vectors (AAV). <i>Methods in Molecular Biology</i> , 2018, 1850, 259-274.	0.4	3
110	Parkin regulates drug-taking behavior in rat model of methamphetamine use disorder. <i>Translational Psychiatry</i> , 2021, 11, 293.	2.4	3
111	Lentiviral Vectors for the Engineering of Implantable Cells Secreting Recombinant Antibodies. <i>Methods in Molecular Biology</i> , 2016, 1448, 139-155.	0.4	2
112	Cellular implants: pioneers in xenotransplantation?. <i>Xenotransplantation</i> , 2003, 10, 96-97.	1.6	1
113	Selective Vulnerability of Neuronal Subtypes in ALS: A Fertile Ground for the Identification of Therapeutic Targets. , 0, , .		1
114	463. Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors for the Production of Adeno-Associated Virus Vectors. <i>Molecular Therapy</i> , 2016, 24, S183-S184.	3.7	1
115	606. Use of a Bicistronic Vector to Silence SOD1 in Motoneurons and Astrocytes for the Treatment of Familial Amyotrophic Lateral Sclerosis. <i>Molecular Therapy</i> , 2016, 24, S240.	3.7	1
116	Viral Vectors. , 2008, , 269-284.		0
117	Application of Viral Vectors to Motor Neuron Disorders. <i>Neuromethods</i> , 2014, , 221-242.	0.2	0
118	465. Transient Production of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Therapy Applications Using Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors. <i>Molecular Therapy</i> , 2015, 23, S184-S185.	3.7	0